{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:29:02Z","timestamp":1788866942877,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation of China,China\u56fd\u5bb6\u81ea\u7136\u79d1\u5b66\u57fa\u91d1\u59d4\u5458\u4f1a \uff0c \u4e2d\u56fd","award":["8237131654"],"award-info":[{"award-number":["8237131654"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"DOI":"10.1007\/s11096-025-02036-5","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:57:59Z","timestamp":1762516679000},"page":"207-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nephrotoxicity of polymyxin B and colistin sulfate in patients with multidrug-resistant gram-negative bacteria infections: a parametric time-to-event analysis"],"prefix":"10.1007","volume":"48","author":[{"given":"Yuanfang","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2036_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.823684","volume":"12","author":"SS Jean","year":"2022","unstructured":"Jean SS, Harnod D, Hsueh PR. Global threat of carbapenem-resistant gram-negative bacteria. Front Cell Infect Microbiol. 2022;12:823684. https:\/\/doi.org\/10.3389\/fcimb.2022.823684.","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"2036_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106633","volume":"60","author":"SS Kanj","year":"2022","unstructured":"Kanj SS, Bassetti M, Kiratisin P, et al. Clinical data from studies involving novel antibiotics to treat multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents. 2022;60(3):106633. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106633.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2036_CR3","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13054-023-04522-6","volume":"27","author":"S Liu","year":"2023","unstructured":"Liu S, Wu Y, Qi S, et al. Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial. Crit Care. 2023;27(1):232. https:\/\/doi.org\/10.1186\/s13054-023-04522-6.","journal-title":"Crit Care"},{"key":"2036_CR4","doi-asserted-by":"publisher","first-page":"1347130","DOI":"10.3389\/fphar.2024.1347130","volume":"15","author":"J Zeng","year":"2024","unstructured":"Zeng J, Leng B, Guan X, et al. Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections. Front Pharmacol. 2024;15:1347130. https:\/\/doi.org\/10.3389\/fphar.2024.1347130.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2036_CR5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/1040841x.2018.1492902","volume":"45","author":"SC Nang","year":"2019","unstructured":"Nang SC, Li J, Velkov T. The rise and spread of mcr plasmid-mediated polymyxin resistance. Crit Rev Microbiol. 2019;45(2):131\u201361. https:\/\/doi.org\/10.1080\/1040841x.2018.1492902.","journal-title":"Crit Rev Microbiol"},{"issue":"3","key":"2036_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1128\/cmr.00006-08","volume":"21","author":"D Landman","year":"2008","unstructured":"Landman D, Georgescu C, Martin DA, et al. Polymyxins revisited. Clin Microbiol Rev. 2008;21(3):449\u201365. https:\/\/doi.org\/10.1128\/cmr.00006-08.","journal-title":"Clin Microbiol Rev"},{"issue":"2","key":"2036_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ja.2013.111","volume":"67","author":"ZZ Deris","year":"2014","unstructured":"Deris ZZ, Akter J, Sivanesan S, et al. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. J Antibiot (Tokyo). 2014;67(2):147\u201351. https:\/\/doi.org\/10.1038\/ja.2013.111.","journal-title":"J Antibiot (Tokyo)"},{"issue":"1","key":"2036_CR8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1080\/22221751.2020.1754133","volume":"9","author":"MAE El-Sayed Ahmed","year":"2020","unstructured":"El-Sayed Ahmed MAE, Zhong LL, Shen C, et al. Colistin and its role in the era of antibiotic resistance: an extended review (2000\u20132019). Emerg Microbes Infect. 2020;9(1):868\u201385. https:\/\/doi.org\/10.1080\/22221751.2020.1754133.","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"2036_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/cid\/cit334","volume":"57","author":"AM Sandri","year":"2013","unstructured":"Sandri AM, Landersdorfer CB, Jacob J, et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis. 2013;57(4):524\u201331. https:\/\/doi.org\/10.1093\/cid\/cit334.","journal-title":"Clin Infect Dis"},{"key":"2036_CR10","doi-asserted-by":"publisher","unstructured":"[Multi-disciplinary expert consensus on the optimal clinical use of the polymyxins in China]. Zhonghua Jie He He Hu Xi Za Zhi. 2021;44(4):292\u2013310. https:\/\/doi.org\/10.3760\/cma.j.cn112147-20201109-01091.","DOI":"10.3760\/cma.j.cn112147-20201109-01091"},{"issue":"4","key":"2036_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1128\/aac.02634-15","volume":"60","author":"MH Rigatto","year":"2016","unstructured":"Rigatto MH, Oliveira MS, Perdig\u00e3o-Neto LV, et al. Multicenter prospective cohort study of renal failure in patients treated with Colistin versus Polymyxin B. Antimicrob Agents Chemother. 2016;60(4):2443\u20139. https:\/\/doi.org\/10.1128\/aac.02634-15.","journal-title":"Antimicrob Agents Chemother"},{"key":"2036_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01900-20","author":"P Wang","year":"2021","unstructured":"Wang P, Zhang Q, Zhu Z, et al. Comparing the population pharmacokinetics of and acute kidney injury due to Polymyxin B in Chinese patients with or without renal insufficiency. Antimicrob Agents Chemother. 2021. https:\/\/doi.org\/10.1128\/aac.01900-20.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2036_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04195-7","volume":"26","author":"J Yang","year":"2022","unstructured":"Yang J, Liu S, Lu J, et al. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria. Crit Care. 2022;26(1):320. https:\/\/doi.org\/10.1186\/s13054-022-04195-7.","journal-title":"Crit Care"},{"issue":"3","key":"2036_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13764","volume":"17","author":"SK Mathew","year":"2024","unstructured":"Mathew SK, Chapla A, Venkatesan P, et al. Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity. Clin Transl Sci. 2024;17(3):e13764. https:\/\/doi.org\/10.1111\/cts.13764.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2036_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"BT Tsuji","year":"2019","unstructured":"Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10\u201339. https:\/\/doi.org\/10.1002\/phar.2209.","journal-title":"Pharmacotherapy"},{"key":"2036_CR16","doi-asserted-by":"publisher","unstructured":"Chinese Research Hospital Association of Critical Care Medicine, Chinese Research Hospital Association Of Evidence Base And Translational Infectious Diseases. [Chinese expert consensus on polymyxins in the clinical practice]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019;31(10):1194\u20138. https:\/\/doi.org\/10.3760\/cma.j.issn.2095-4352.2019.10.003.","DOI":"10.3760\/cma.j.issn.2095-4352.2019.10.003"},{"key":"2036_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.967412","volume":"13","author":"YL Xie","year":"2022","unstructured":"Xie YL, Jin X, Yan SS, et al. Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients. Front Pharmacol. 2022;13:967412. https:\/\/doi.org\/10.3389\/fphar.2022.967412.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2036_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.kint.2020.04.020","volume":"98","author":"M Ostermann","year":"2020","unstructured":"Ostermann M, Bellomo R, Burdmann EA, et al. Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) conference. Kidney Int. 2020;98(2):294\u2013309. https:\/\/doi.org\/10.1016\/j.kint.2020.04.020.","journal-title":"Kidney Int"},{"issue":"6","key":"2036_CR19","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/cpt.3048","volume":"114","author":"Y Liu","year":"2023","unstructured":"Liu Y, Kuang Y, Hai M, et al. Model-informed dosing regimen of Ticagrelor in Chinese patients with acute coronary syndrome. Clin Pharmacol Ther. 2023;114(6):1342\u20139. https:\/\/doi.org\/10.1002\/cpt.3048.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2036_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.107031","volume":"63","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Dong R, Huang Y, et al. Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: a real-world, retrospective cohort study. Int J Antimicrob Agents. 2024;63(1):107031. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107031.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2036_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s15010-007-6104-1","volume":"35","author":"ME Falagas","year":"2007","unstructured":"Falagas ME, Kasiakou SK. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis. Infection. 2007;35(1):3\u201310. https:\/\/doi.org\/10.1007\/s15010-007-6104-1.","journal-title":"Infection"},{"issue":"5","key":"2036_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1378\/chest.11-1396","volume":"141","author":"BS Smith","year":"2012","unstructured":"Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 2012;141(5):1327\u201336. https:\/\/doi.org\/10.1378\/chest.11-1396.","journal-title":"Chest"},{"issue":"12","key":"2036_CR23","doi-asserted-by":"publisher","first-page":"7331","DOI":"10.1128\/aac.03510-14","volume":"58","author":"M Boisson","year":"2014","unstructured":"Boisson M, Jacobs M, Gr\u00e9goire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331\u20139. https:\/\/doi.org\/10.1128\/aac.03510-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2036_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12967-021-03111-x","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, Qi S, Duan X, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. J Transl Med. 2021;19(1):431. https:\/\/doi.org\/10.1186\/s12967-021-03111-x.","journal-title":"J Transl Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02036-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:19:01Z","timestamp":1768972741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["2036"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02036-5","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The study was approved by the Ethics Committee of Xiangya Third Hospital (Approval Number: 23291, approval date May 11, 2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}